ARA-290

Research Phase

ARA-290 (Cibinetide)

Aliases
Cibinetide, pHBSP
Administration
Subcutaneous injection

Research and regulatory

Development stage

Phase 2 clinical trials completed for neuropathic pain and sarcoidosis-associated small fiber neuropathy; not yet FDA approved.

Legal and regulatory

Investigational compound; not FDA approved for any indication.

Side effects

Generally well-tolerated in trials